1. Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction
- Author
-
Luk, CW, Lee, V, Leung, Y, Ng, MHL, Mejstrikova, E, Hrusak, O, Ling, SC, Li, CH, Lee, ACW, Cheuk, KLD, Ha, SY, Leung, AWK, Shing, MMK, Cheng, CK, Ip, RKL, Chan, NPH, Li, CK, Lau, KM, and Cheng, SH
- Subjects
Oncology ,Male ,Pathology ,Multivariate analysis ,Neoplasm, Residual ,Oncogene Proteins, Fusion ,lcsh:Medicine ,Pediatrics ,Polymerase Chain Reaction ,Hematologic Cancers and Related Disorders ,Molecular cell biology ,DNA amplification ,Recurrence ,hemic and lymphatic diseases ,Blood plasma ,Antineoplastic Combined Chemotherapy Protocols ,Longitudinal Studies ,Child ,lcsh:Science ,Multidisciplinary ,medicine.diagnostic_test ,Hematology ,DNA, Neoplasm ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Flow Cytometry ,Acute Lymphoblastic Leukemia ,Prognosis ,Nucleic acids ,medicine.anatomical_structure ,Real-time polymerase chain reaction ,Child, Preschool ,Cohort ,Medicine ,Female ,Research Article ,Risk ,medicine.medical_specialty ,Adolescent ,Clinical Research Design ,Antineoplastic Agents ,Disease-Free Survival ,Flow cytometry ,Internal medicine ,Leukemias ,medicine ,Humans ,Pediatric Hematology ,Statistical Methods ,Immunoassays ,Childhood Acute Lymphoblastic Leukemia ,Biology ,business.industry ,lcsh:R ,Infant ,DNA ,Minimal residual disease ,body regions ,Pediatric Oncology ,Immunologic Techniques ,Clinical Immunology ,lcsh:Q ,Bone marrow ,business ,Cytometry - Abstract
Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute lymphoblastic leukemia. In ALL-IC-BFM 2002 study, we employed a standardized method of flow cytometry MRD monitoring for multiple centers internationally using uniformed gating, and determined the relevant MRD-based risk stratification strategies in our local patient cohort. We also evaluated a novel method of PCR MRD quantitation using peripheral blood plasma. For the bone marrow flow MRD study, patients could be stratified into 3 risk groups according to MRD level using a single time-point at day-15 (Model I) (I-A: 10%), or using two time-points at day-15 and day-33 (Model II) (II-A: day-15
- Published
- 2013